HOBSCOTCH-YOUTH and Young Adults
NCT07735715 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300
Last updated 2026-07-30
Summary
The goal of this clinical trial is to learn more about the home-based epilepsy self-management program, HOBSCOTCH, for improving cognitive function (thinking and memory) and quality of life specifically in young adults, ages 18 - 29 years, who have epilepsy. It will also learn if a modification of the program for youth with epilepsy, ages 13 - 17, improves thinking and memory and quality of life and reduces stress for their parents.
Researchers will enroll 260 young adults with epilepsy and 40 youth with epilepsy and their parent or guardian. Researchers will compare responses to questionnaires and surveys before and after participation in the HOBSCOTCH program to see if thinking, memory and quality of life have improved for young adults and youth with epilepsy and to see if parents have improved quality of life as well.
Participants will:
* Attend 9 weekly one-hour sessions of the HOBSCOTH program in their homes with a one-on-one coach using their computer or their phone; youth with epilepsy (ages 13 - 17) will attend alongside a parent or legal guardian.
* Keep a short daily diary about their seizures and activity in the program using a smart phone app(lication)
* Complete surveys and questionnaires before HOBSCOTCH and 3 months and 6 months later.
There are no study visits to a medical center. HOBSCOTCH is a virtual or telehealth intervention.
Conditions
- Epilepsy
- Cognitive Dysfunction, Cognitive Disorder
- Memory and Thinking Problems
Interventions
- OTHER
-
HOBSCOTCH/HOBSCOTCH-YOUTH
HOBSCOTCH (HOme Based Self-Management and COgnitive Training CHanges Lives) is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care, for people with epilepsy and other neurological disorders. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-YOUTH is an adaptation of the HOBSCOTCH program for youth ages 13 - 17 who have epilepsy.
Sponsors & Collaborators
-
Epilepsy Wellness Advocates
collaborator UNKNOWN -
Dartmouth-Hitchcock Medical Center
lead OTHER
Principal Investigators
-
Elaine T. Kiriakopoulos, MD, MPH, MSc · Dartmouth-Hitchcock/Geisel School of Medicine-Dartmouth
Study Design
- Allocation
- NA
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 13 Years
- Max Age
- 29 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-09-01
- Primary Completion
- 2028-09-01
- Completion
- 2029-03-01
Countries
- United States
Study Locations
More Related Trials
-
Stimulation of the Thalamus for Arousal Restoral in Temporal Lobe Epilepsy
NCT04897776 ·Status: COMPLETED ·Phase: NA
-
Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage
NCT02631759 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial : TROCC (Quick Oral Treatment of Cluster Epileptic Seizures)
NCT00376766 ·Status: TERMINATED ·Phase: PHASE3
-
Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
NCT02098759 ·Status: UNKNOWN ·Phase: NA
-
Computerized Cognitive Training in Epilepsy
NCT02726191 ·Status: WITHDRAWN ·Phase: NA
-
Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis(SESTB)
NCT06436547 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Web-based Intervention to Improve Executive Functioning in Teens With Epilepsy (Epilepsy Journey)
NCT02925663 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures
NCT00422110 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking
NCT06275685 ·Status: RECRUITING ·Phase: NA
-
Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients
NCT02371200 ·Status: COMPLETED
-
Human Intracranial Electrophysiology
NCT05529264 ·Status: RECRUITING ·Phase: NA
-
Cholinergic Enhancement of Theta
NCT07228338 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy
NCT00175851 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study of Cannabidiol for Drug-Resistant Epilepsies
NCT03014440 ·Status: NO_LONGER_AVAILABLE
-
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
NCT04485104 ·Status: TERMINATED ·Phase: PHASE3
-
Assessing Comorbidities in Epilepsy Using Eye Movement Recordings
NCT06310772 ·Status: COMPLETED
-
The Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy
NCT06097195 ·Status: RECRUITING ·Phase: NA
-
Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures
NCT02687711 ·Status: COMPLETED
-
Subcutaneous EEG: Forecasting of Epileptic Seizures
NCT04061707 ·Status: COMPLETED
-
LevetIracetam in Patients Being Treated for Epilepsy
NCT02356731 ·Status: COMPLETED
-
Enhancing Epilepsy Management With Precision Deep Brain Stimulation
NCT06364085 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Anterior Temporal Epilepsy Neuropsychological Assessment of Faces
NCT02888925 ·Status: UNKNOWN ·Phase: NA
-
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
NCT02318537 ·Status: WITHDRAWN ·Phase: PHASE3
-
Epidiolex and Drug Resistant Epilepsy in Children
NCT02397863 ·Status: AVAILABLE
-
NYU Epilepsy Self-Management Study
NCT07087821 ·Status: RECRUITING ·Phase: NA